TRIM21 and rheumatoid arthritis: Anti-Ro52 carriers presented more frequently CKD (p = 0.022) or pSS (p < 0.001), while they had less frequently dyslipidemia (p = 0.021), active exposure to corticosteroids (p = 0.012) and immunosuppressants (p < 0.001), or a diagnosis of RA (p < 0.001).